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COPD = chronic obstructive pulmonary disease; EGF(R) = epidermal growth factor (receptor); MAPK = mitogen-activated protein kinase; TGF =
transforming growth factor; TNF = tumor necrosis factor.
Available online http://respiratory-research.com/content/2/2/085
Introduction
Epidermal growth factor (EGF) was discovered by Cohen,
and he and his colleagues subsequently extended our knowl-
edge of the mechanisms of action of EGF and its receptor
EGFR [1]. EGFR is a 170 kDa membrane glycoprotein,
which is activated by ligands such as EGF, transforming
growth factor (TGF)-a, heparin-binding EGF, amphiregulin,
betacellulin, and epiregulin. These proteins are synthesized
as transmembrane precursors and are cleaved proteolytically
by metalloproteases to release the mature growth factor,
which can interact with EGFR and cause its activation.
Epidermal growth factor expression and
activation causes goblet-cell metaplasia in
airways
The discovery that a human epidermoid (A-431) cancer
cell line contains high concentrations of EGFR led to
extensive investigation into the role of the EGFR cascade
in epithelial cell multiplication (cancer). Although growth
factors can act as transforming proteins, it was recently
hypothesized that EGFR activation may also be involved in
epithelial differentiation into mucin-containing goblet cells
by specific inflammatory mediators. The hypothesis was
supported by the following observations. First, muco-
substances can be detected in dysplastic lesions and in
foci of carcinoma in situ in human airways, and in tracheal
lesions induced by carcinogens in animals [2]. The coexis-
tence of mucin-containing cells and cancer cells suggests
the possibility of a common progenitor. Second, Clara
cells (also called ‘nongranulated secretory cells’) are
believed to be the progenitor cells for bronchiolar carci-
noma [3], and various studies also implicate these cells as
precursors of goblet cells [4].
Takeyama  et al [4] hypothesized that EGFR expression
and activation would result in mucin expression and
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goblet-cell metaplasia. First, NCI-H292 cells (an epider-
moid carcinoma cell line that expresses EGFR constitu-
tively) were studied. EGFR ligands (EGF, TGF-a) caused
expression of the MUC5AC mucin (a predominant airway
mucin) gene. Interaction of EGFR with its ligands led to
EGFR tyrosine kinase phosphorylation, and a selective
EGFR tyrosine kinase inhibitor (BIBX1522) blocked
MUC5AC expression induced by EGFR ligands, thereby
implicating EGFR activation in mucin production. Second,
the airways of pathogen-free rats do not express EGFR
constitutively, and contain few goblet cells [4]. Instillation
of tumor necrosis factor (TNF)-a induced EGFR expres-
sion in the airway epithelium, and subsequent instillation of
EGFR ligand (TGF-a) induced mucin expression.
BIBX1522 prevented this response in a dose-dependent
manner, implicating EGFR activation in the goblet-cell
response. A diagram of this EGFR cascade that is respon-
sible for mucin production is provided (Fig. 1).
Epithelial cell multiplication versus cell
differentiation
In cancer cells, EGFR activation leads to cell multiplica-
tion. In normal airway epithelium, however, goblet cells
appear to form from precursor (Clara) cells in the epithe-
lium. Thus, in Sendai virus-induced goblet-cell metaplasia
in pathogen-free rats, developing mucin-containing cells
did not incorporate [3H]thymidine, suggesting that cell
mitosis was not involved in synthesis of mucin mRNA [5].
In endotoxin-induced goblet-cell metaplasia in rat nasal
septum, pretreatment with colchicine (which causes
metaphase blockade) did not inhibit the production of
goblet cells [6]. The mitotic rate and the total number of
epithelial cells was unchanged, which led Shimizu et al [6]
to conclude that the new goblet cells were produced by
direct conversion of Clara cells. Finally, EGFR expression
and activation causes goblet-cell metaplasia without
changing the total number of epithelial cells, indicating
that the number of goblet cells increases and the number
of Clara cells decreases equivalently, thus implicating a
differentiation process in goblet-cell development [4].
Stimuli for mucin synthesis: role of the
epidermal growth factor receptor cascade
Many chronic inflammatory diseases of the airway are
associated with mucus hypersecretion; this may con-
tribute to asthma mortality [7,8]. Hypersecretion is also
associated with nasal polyps [9], and in cystic fibrosis
hypersecretion is associated with bacterial infections,
especially with Pseudomonas aeruginosa [10]. In addi-
tion, cigarette smoking is a major cause of death in
chronic obstructive pulmonary disease (COPD) [11], and
the airways of smokers contain more goblet cells than do
those of nonsmokers [12]. Exposure to cigarette smoke
results in hypersecretion in the airways [13]. Orotracheal
intubation-induced injury and other types of mechanical
damage to the airway epithelium also result in mucus
hypersecretion [14–16]. Neutrophils and their products
are implicated in cystic fibrosis [10], COPD [11], and
acute severe asthma [17].
Asthma and nasal polyps
The secretory state of the airways may vary considerably
among asthmatic persons. Amishima et al [18] reported
increased EGFR expression in submucosal glands and the
surface epithelium of lungs removed surgically from asth-
matic persons, although the severity of disease was not
assessed. Takeyama et al [19] found increased numbers
of goblet cells in biopsy specimens removed from the
proximal airways of mildly asthmatic persons as compared
with specimens from healthy nonasthmatic persons. EGFR
and MUC5AC gene expression was increased, but varied,
among the asthmatic persons. There was, however, a pos-
itive correlation between EGFR immunoreactivity and the
amount of mucin staining, and Takeyama et al [19] sug-
gested that the variability was related to the degree of
‘activity’ of the disease.
Nasal polyp epithelium contains increased numbers of
goblet cells [9]. Specimens from healthy persons did not
express EGFR strongly while four out of eight polyp speci-
mens showed strong EGFR expression. TNF-a, which
induces EGFR expression [4], was found (mostly in
eosinophils) in polyps that express EGFR, suggesting that
TNF-a in eosinophils may be responsible for EGFR
expression in polyps. Burgel et al [9] also noted that neu-
trophils were more concentrated in the epithelium of
EGFR-positive than in the epithelium of EGFR-negative
polyps. It has been speculated that EGFR activation in
polyps could occur via the release of TGF-a from
Figure 1
The mechanism of EGFR expression and activation. Stimulation of airway
epithelial cells with TNF-a causes EGFR expression (the extracellular
and intracellular parts of EGFR are shown). EGFR ligands (produced by
epithelial or nearby cells) bind to EGFR, resulting in EGFR tyrosine
phosphorylation and a subsequent downstream cascade, which causes
mucin gene and protein expression.c
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eosinophils [20] or by transactivation of EGFR by oxygen
free radicals released from neutrophils [21].
These clinical studies have limitations, but their findings
suggest that goblet-cell metaplasia could result from an
interaction among multiple cells (eg epithelial cells,
eosinophils, and neutrophils).
Clinical studies may be informative, but carefully controlled
studies in animals and in cells in vitro may also provide
important insights into basic mechanisms. For instance,
allergic sensitization with ovalbumin causes goblet-cell
metaplasia in rodents [22], and the T-helper-2 cytokines
interleukin-4 and interleukin-13 have been implicated in
this process [23]. In interleukin-5-knockout mice, ovalbu-
min sensitization no longer leads to eosinophil recruitment
after allergen exposure, but goblet-cell metaplasia still
occurs [24]. Cohn et al [24] concluded that eosinophils
were not required for allergic goblet-cell metaplasia,
although neutrophils were not evaluated. Takeyama et al
[4] showed that ovalbumin sensitization induced goblet-
cell metaplasia and EGFR-positive staining in the epithe-
lium, and that selective EGFR inhibitors prevented this
process, implicating EGFR.
Furthermore, an antibody to the interleukin-4 receptor was
reported [25] to prevent ovalbumin-induced goblet-cell
metaplasia. EGFR inhibitors were also effective, leading
Shim et al [26] to suggest that T-helper-2 cytokines acti-
vate an EGFR cascade. Selective EGFR inhibitors also
prevented interleukin-13 goblet-cell metaplasia. IL-13 instil-
lation also resulted in neutrophil recruitment into the
airways [26], and the infiltrating neutrophils expressed
TNF-a. An interleukin-8-blocking antibody inhibits inter-
leukin-13-induced neutrophil recruitment and mucin pro-
duction. Thus, interleukin-13 causes goblet-cell metaplasia
indirectly by neutrophil recruitment and activation, perhaps
releasing oxygen free radicals that then cause EGFR trans-
activation and goblet-cell metaplasia [21].
These studies show the importance of the EGFR cascade
in allergic mucus hypersecretion. They also implicate neu-
trophils in allergic goblet-cell metaplasia in rodents.
Perhaps neutrophils have been ignored previously in such
allergic responses because allergens cause early recruit-
ment of neutrophils, which initiate an EGFR gene and
protein cascade, which in turn initiates mucin gene and
protein expression. Neutrophils disappear from the
airways when goblet-cell metaplasia is obvious (24–48 h
later), although they appear to be important in experimen-
tal allergen-induced mucus hypersecretion.
Cigarette smoke and activated neutrophils
Cigarette smoke exposure in animals also results in mucus
hypersecretion [13]. Takeyama et al [27] reported that
exposure to cigarette smoke upregulated EGFR mRNA
expression and induced EGFR-specific tyrosine phospho-
rylation, resulting in upregulation of MUC5AC mucin
mRNA and protein production, effects that were inhibited
completely by selective EGFR tyrosine kinase inhibitors.
Approximately half of the response was also inhibited by
antioxidants, implicating a role for oxygen free radicals,
although the remainder could have been due to other sub-
stances such as acrolein [28]. Neutrophil infiltration in
airways is characteristic of patients with COPD, and acti-
vated neutrophils increase EGFR tyrosine phosphorylation
and subsequent MUC5AC expression at both the mRNA
and protein levels in NCI-H292 cells. These effects can be
blocked by selective EGFR inhibitors. Neutrophil super-
natant-induced EGFR tyrosine kinase phosphorylation and
MUC5AC synthesis is also inhibited by antioxidants [21].
These results implicate oxidative stress produced by neu-
trophils in mucin synthesis in airways.
Mechanical ‘wounding’
EGFR enhances repair of sheep tracheal epithelial injury
[29], and morphologically damaged bronchial epithelial
repair is accelerated by EGFR activation [30]. The
authors of those studies did not comment on goblet-cell
metaplasia. However, in horses, orotracheal intubation
results in mucus hypersecretion [14], and mechanical
denudation of hamster airways results in secretory-cell
metaplasia [15]. Lee et al [16] instilled irregular agarose
plugs into rat airways to produce irritation, which also
resulted in a profound increase in goblet cells. Plugged
bronchi showed EGFR upregulation, and selective EGFR
inhibitors prevented agarose-induced goblet-cell metapla-
sia. Peribronchial infiltration with neutrophils was also
observed in plugged airways. Cyclophosphamide pre-
vented agarose-induced neutrophil recruitment and
goblet-cell metaplasia. Activated neutrophils produce
TNF-a, and an anti-TNF-a antibody also prevented
agarose-induced goblet-cell metaplasia. These findings
implicate neutrophils and TNF-a in wound-induced EGFR
activation and goblet-cell metaplasia.
These studies of mechanical damage to airways may be
of clinical relevance for two reasons. First, epithelial
damage is believed by some investigators to occur in
asthma, and this damage could induce mucus hyper-
secretion. Second, because chronic intubation leads to
mucus hypersecretion in horses [14], a similar effect is
likely to occur in humans. It would be difficult to differenti-
ate secretions generated in the lower airways and trans-
ported to the trachea from those secretions generated at
the site of intubation. Perhaps during the day the secre-
tions would be coughed up and aspirated, but during
sleep cough is suppressed and mucus produced in the
upper airways would be aspirated into the lungs, leading
to mucus plugging and impairing gas exchange. The
importance of such a mechanism should be evaluated in
patients in the intensive care environment.
Available online http://respiratory-research.com/content/2/2/085Bacterial infection
Mucus hypersecretion is characteristic of cystic fibrosis
[10], and P. aeruginosa infections are associated with
deterioration and death from cystic fibrosis. This has led to
studies of the effect of Gram-negative bacterial products
(including endotoxin) on mucin production; for example,
Escherichia coli endotoxin increases epithelial mucosub-
stances [31], causes goblet-cell metaplasia in rat nose
[32], and increases mucin synthesis in the lower airways
[33]. Li et al [34] reported that P. aeruginosa activates the
c-Src-Ras-MAPK kinase signaling pathway, leading to
activation of nuclear factor-kB, which in turn activates
mucin synthesis [35]. Kohri et al [36] reported that selec-
tive EGFR inhibitors prevent P. aeruginosa-induced mucin
synthesis in human airway epithelial (NCI-H292) cells,
again implicating EGFR activation.
Conclusion
Many chronic inflammatory airway diseases (eg asthma,
cystic fibrosis, COPD, and nasal polyps) are associated
with mucus hypersecretion. A wide variety of stimuli (eg
allergens, bacteria, mechanical injury, cigarette smoke,
and cytokines and activated neutrophils) cause the airway
epithelium to differentiate into mucin-producing (goblet)
cells via activation of an EGFR cascade. Airways of
healthy individuals contain few goblet cells, but develop-
ment of mature goblet cells de novo occurs within 3 days
[16] and degranulation occurs within minutes [37]. In
peripheral airways, this may lead to mucus plugging [38],
which may not cause early symptoms and may be difficult
to diagnose, but may progress rapidly to impairment of
gas exchange and death. Mucus hypersecretion probably
fluctuates with inflammation in disease.
Effective therapy for hypersecretion does not currently
exist, but the novel pathway involved in EGFR expression
and activation suggests new approaches to therapy for
mucus hypersecretion.
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